Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ligand Pharm
(NQ:
LGND
)
73.90
+1.58 (+2.18%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Ligand Pharm
< Previous
1
2
3
Next >
7 Small-Cap Stocks for the Thinking Speculator
April 08, 2024
While these small-cap stocks may be miles away from Wall Street’s spotlight, they’re compelling enough to deliver some big surprises.
Via
InvestorPlace
Why Is Ligand Pharmaceuticals Stock Trading Higher Today?
February 27, 2024
Ligand Pharmaceuticals beats Q4 2023 sales estimates at $28.1 million, with strong core Captisol and royalty figures. CEO Todd Davis highlights transformative 2023 and optimistic guidance for 2024.
Via
Benzinga
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 27, 2024
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via
Benzinga
Ligand Pharmaceuticals's Earnings: A Preview
February 26, 2024
Via
Benzinga
Where Ligand Pharmaceuticals Stands With Analysts
September 19, 2023
Via
Benzinga
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
February 27, 2024
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 27, 2024
Via
Benzinga
Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
November 28, 2023
Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent
Via
Benzinga
Ligand Pharma Updates Annual Guidance As It Spins Out Pelican Subsidiary
September 19, 2023
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) entered into a merger agreement under which its subsidiary, Pelican Technology Holdings Inc, has become a wholly owned subsidiary of Primrose Bio...
Via
Benzinga
Analyst Expectations for Ligand Pharmaceuticals's Future
August 23, 2023
Via
Benzinga
Recap: Ligand Pharmaceuticals Q1 Earnings
May 04, 2023
Via
Benzinga
Ligand Pharmaceuticals Earnings Preview
February 21, 2023
Via
Benzinga
Roth Capital Maintains Buy Rating for Ligand Pharmaceuticals: Here's What You Need To Know
December 23, 2022
Via
Benzinga
Why Are Novan Shares Nosediving Today?
July 17, 2023
Novan Inc (NASDAQ: NOVN) shares are trading lower after Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has offered to
Via
Benzinga
3 Stocks That Smart Investors Should Be Flocking to Now
May 30, 2023
Investors may want to detour away from the obvious trades and consider compelling top stocks for smart investors.
Via
InvestorPlace
Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial
May 16, 2023
Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in
Via
Benzinga
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
February 21, 2023
Via
Benzinga
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
January 31, 2023
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...
Via
Benzinga
Earnings Scheduled For February 22, 2023
February 22, 2023
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.
Via
Benzinga
Tesla To $175? Here Are 10 Other Price Target Changes For Friday
December 23, 2022
Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market...
Via
Benzinga
Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says
December 16, 2022
Credit Suisse initiated coverage on OmniAb Inc (NASDAQ: OABI) with an Outperform rating and a price target of $13.
Via
Benzinga
Ligand Pharma Issues Mixed Guidance For FY23
December 13, 2022
At its Investor and Analyst Day event, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided an overview of Ligand's corporate structure and business following the successful spin-off of its...
Via
Benzinga
Earnings Outlook For Ligand Pharmaceuticals
November 04, 2022
Ligand Pharmaceuticals (NASDAQ:LGND) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Ligand...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 02, 2022
Gainers Monopar Therapeutics (NASDAQ:MNPR) shares increased by 53.0% to $4.09 during Wednesday's pre-market session. The company's market cap stands at $52.0 million.
Via
Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...
Via
Benzinga
Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients
August 25, 2022
Via
Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 24, 2022
Via
Benzinga
Ligand Pharmaceuticals: Q2 Earnings Insights
August 08, 2022
Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q2 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Ligand Pharmaceuticals...
Via
Benzinga
Barclays Maintains Overweight Rating for Ligand Pharmaceuticals: Here's What You Need To Know
July 05, 2022
Barclays has decided to maintain its Overweight rating of Ligand Pharmaceuticals (NASDAQ:LGND) and lower its price target from $165.00 to $157.00. Shares of Ligand Pharmaceuticals are trading up 1.79%...
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.